Skip to Main Content Skip to Site Map Skip to Accessibility Statement


Trial Acronym MARCH
Clinical Area Critical Care
Trial Title Mucoactives in Acute Respiratory failure: Carbocisteine and Hypertonic saline
Status Open to Recruitment
Trial Registration

  • Recruitment
    Recruitment Target 1956
    Date Open to Recruitment February 2022
    Recruitment  1322 as of March 2024
    Date Closed to Recruitment Ongoing
  • Trial Design
    Trial Design A 2×2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost effectiveness trial with internal pilot, to determine whether mucoactives (carbocisteine and hypertonic saline) in critically ill patients with acute respiratory failure (ARF) reduce duration of mechanical ventilation
    Study Aim Aim : To determine whether use of mucoactives in critically ill patients with acute respiratory failure improves outcomes and is cost effective, compared to usual airway clearance management

    Objectives : To conduct a large, UK, multi-centre, pragmatic, randomised controlled trial to:
    1. Determine the clinical effectiveness of two mucoactives (carbocisteine or hypertonic saline), or a combination of both, on duration of mechanical ventilation (primary outcome), and a range of secondary clinical and safety outcomes
    2. Estimate, in an integrated economic evaluation, the cost-effectiveness of the mucoactives

  • Chief Investigator (CI)
    Chief Investigator


    Professor Danny McAuley, Queen’s University Belfast

    Co-Chief Investigator


    Dr Bronwen Connolly, Queen’s University Belfast

  • Sponsor(s) & Funder(s)
    Sponsor Belfast Health and Social Care Trust
    Funder National Institute for Health and Care Research
    Health Technology Assessment Programme; NIHR130454
  • Patient Information